SCHEMBL2193095

SCHEMBL2193095

Cc1c(F)cccc1Nc1nc(O)ccc1[N+](=O)[O-]

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 0.44
KMT2A Q03164 8/20 0.44
POLB P06746 5/20 0.39
CYP2C19 P33261 2/20 0.38
MAPT P10636 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
L3MBTL1 Q9Y468 3/20 0.38
TDP1 Q9NUW8 3/20 0.37
CRHBP P24387 1/20 0.37
CRHR2 Q13324 1/20 0.37
LMNA P02545 2/20 0.36
ALDH1A1 P00352 3/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CYP2C9 P11712 1/20 0.36
GAA P10253 2/20 0.35
PKM P14618 1/20 0.35
MAPK1 P28482 1/20 0.35
BLM P54132 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2194211 0.87 MEN1 (0.37) MEN1KMT2APOLBMAPTL3MBTL1
SCHEMBL2192732 0.87 KMT2A (0.54) MEN1KMT2APOLBCYP2C19MAPT
SCHEMBL2197093 0.87 MEN1 (0.46) MEN1KMT2APOLBMAPTL3MBTL1
SCHEMBL2191711 0.85 MAPT (0.37) MEN1KMT2APOLBMAPTL3MBTL1
SCHEMBL2195456 0.85 MAPT (0.46) MEN1KMT2APOLBCYP2C19MAPT
SCHEMBL2192755 0.82 KMT2A (0.51) MEN1KMT2APOLBCYP2C19MAPT
SCHEMBL2195364 0.80 KMT2A (0.41) MEN1KMT2APOLBCYP2C19MAPT
SCHEMBL2193522 0.78 PIK3CD (0.39) MAPTALDH1A1SMN1; SMN2GAAHTT
SCHEMBL2191805 0.77 KMT2A (0.46) MEN1KMT2APOLBMAPTL3MBTL1
SCHEMBL2191393 0.76 CXCR2 (0.44) MEN1KMT2APOLBMAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8507473-B2 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders ARENA PHARMACEUTICALS, INC. (US) 2013-08-13 US disclosed
US-20110172209-A1 3H-IMIDAZO[4,5-B]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS ARENA PHARMACEUTICALS, INC. (US) 2011-07-14 US disclosed
WO-2010030360-A1 3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS ARENA PHARMACEUTICALS, INC. (US) 2010-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172209-A1 3H-IMIDAZO[4,5-B]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS GPR84, GPR119, GPR65 MEN1 2445/4885KMT2A 3713/4885POLB 3282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.